DOI: https://doi.org/10.26641/2307-0404.2018.2(part1).129513

The influence of adequate drug therapy on the clinical symptoms and level of serum amyloid A in patients with chronic obstructive pulmonary disease.

T. A. Pertseva, D. S. Koval

Abstract


The aim of our research was to study the dynamics of the level of SAA in COPD patients in the stable phase of the pathological process against the background of basic therapy. We studied 37 stable COPD patients with II-IV degree of ventilation violations according to the GOLD classification, distributed in two subgroups depending on the adequacy of taking basic therapy. Stable COPD patients, irrespective of the severity of the course of the disease in conditions of inadequate treatment have greater symptom severity, the number of exacerbations over the past year and the level of SAA than patients taking long-term therapy according to COPD severity. Taking therapy corresponding to the severity of the disease within three months by COPD patients helps to reduce the severity of COPD symptoms to the level of these indicators in patients taking adequate therapy for a longer period of time. Treatment of COPD patients which corresponds to the severity of the disease within three months contributes to a significant reduction of SAA level.


Keywords


chronic obstructive pulmonary disease; systemic inflammation; serum amyloid A

References


[Order of the Ministry of Health of Ukraine N 555 dated June 27, 2013 "An Approval and Im­plementation of Medical-Technological Documents on Standardization of Medical Assistance in the Case of Chronic Obstructive Pulmonary Disease]. Kyiv. 2013;146. Ukrainian.

Abo-Sabe S, Abo Bakr BW. Serum amyloid a in chronic obstructive pulmonary disease AsianAcademyofManagement Journal. 2008;6:27-34.

Gan WQ, Man SF, Senthilselvan A. Association between chronic obstructive pulmonary diseaseand sys­temic inflammation: a systematic review and a meta­analysis Thorax. 2004;59:574-80.

Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, ma­nagement, and prevention of chronic obstructive pulmonary disease. [Internet]. Update 2017;14. Available from: http://www.goldcopd.org/uploads/­users/files/GOLD_Report_2017_Jan23.pdf.

Jovanovic DB. Clinical importance of determi­nation of serum amyloid A. Srp. Arh. Celok. Lek. 2004;132(7-8):267-71.

Paul SF, Sin D. Effects of Corticosteroids on Sys­temic Inflammation in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society. 2005;2:78-82.

Wouters EF, Wouters BB, Augustin IM, Franssen FM. Personalized medicine and chronic obstructive pul­monary disease. Curr Opin Pulm Med. 2017;23(3):241-6.

Smith ST, Yerkovich DJ, Towers MA, Car­roll ML. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37:516-22.

Bozinovski S, Hutchinson A, Thompson ML. Serum amyloid A is a biomarker of acute exacerbation of COPD. Am J RespirCrit Care Med: 2007;177:269-78.

Urieli-Shoval S, Linke RP et al. Expres­sion and fun­ction of serum amyloid A, major acute-phase protein, in no­rmal and disease states. Curr. Opin. Hematol. 2000;7(1):64-69.


GOST Style Citations


  1. Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при хронічному обструктивному за­хворю­ванні легень: Наказ МОЗ України № 555 від 27.06.2013 р. – Київ, 2013. – 146 с.
  2. Abo-Sabe S. Serum amyloid a in chronic obstruc­tive pulmonary disease / S. Abo-Sabe, B. W. Abo Bakr// Asian Acad. Management J. – 2008. – Vol. 6. – P. 27-34.
  3. Gan W.Q. Association between chronic obstruc­tive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis / W.Q. Gan, S.F. Man, A. Senthilselvan // Thorax. – 2004. – Vol. 59. – P. 574-580.
  4. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, ma­nagement, and prevention of chronic obstructive pulmonary disease. Update 2017. [Electronic resourse] – P. 14 – Access mode: http://www.goldcopd.org/uploads/­users/files/GOLD_Report_2017_Jan23.pdf.
  5. Jovanovic D.B. Clinical importance of determi­nation of serum amyloid A / D.B. Jovanovic // Srp. Arh. Celok. Lek. ‒ 2004. – Vol. 132, N 7-8. – P. 267-271.
  6. Paul S.F. Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease / S.F. Paul, D. Sin // Proceedings Am. Thoracic Society. – 2005. – Vol. 2. – Р. 78-82.
  7. Personalized medicine and chronic obstructive pulmonary disease / E.F. Wouters, B.B. Wouters , I.M. Augustin, F.M Franssen // Curr. Opin. Pulm. Med. – 2017. – Vol. 23, N 3. – P. 241-246.
  8. Reduced soluble receptor for advanced glycation end-products in COPD / S.T. Smith, D.J. Yerkovich, M.A. Towers, M.L. Carroll // Eur. Resp. J. – 2011. – Vol. 37. – Р. 516-522.
  9. Serum amyloid A is a biomarker of acute exa­cerbation of COPD /S. Bozinovski1, A. Hutchinson, M. Thompson2, L. MacGregor [et al.] // Am. J. Resp. Crit. Care. Med. – 2007. – Vol. 177. – P. 269-278.
  10. Urieli-Shoval S. Expression and function of se­rum amyloid A, a major acute-phase protein, in normal and disease states / S. Urieli-Shoval, R.P. Linke, Y. Mat­zner // Curr. Opin. Hematol. – 2000. – Vol. 7, N 1. – P. 64-69.